Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 13,461 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft-Versus-Host-Disease Clear all
Completed Phase 1Phase 2 Interventional

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

NCT01194037
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Genotype 1
Interventions
recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • National City, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

NCT01188772
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain

NCT00108381
View directory record Official record
Conditions
Back Pain
Interventions
tailored cognitive behavior therapy, standard care
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease

NCT02058719
View directory record Official record
Conditions
HIV, Smoking, COPD
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

NCT02933450
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Patiromer 25.2 g
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Tafasitamab, Idelalisib, Venetoclax
Biological · Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Emotional Awareness and Expression Therapy (EAET) or Cognitive Behavior Therapy (CBT) for Older Veterans With Chronic Musculoskeletal Pain

NCT03844880
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Emotional Awareness and Expression Therapy, Cognitive Behavior Therapy
Behavioral
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

NCT00899496
View directory record Official record
Conditions
Cancer
Interventions
immunological diagnostic method, physiologic testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

NCT00124241
View directory record Official record
Conditions
Hepatitis B
Interventions
telbivudine, lamivudine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years
Timeline
Ends 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Neuromodulatory Treatments for Pain Management in TBI

NCT03418129
View directory record Official record
Conditions
Chronic Pain, Traumatic Brain Injury, Posttraumatic Stress Disorder
Interventions
Mindfulness, Neurofeedback, Relaxation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

NCT04148872
View directory record Official record
Conditions
Synkinesis
Interventions
Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial

NCT06123195
View directory record Official record
Conditions
Chronic Kidney Disease, Constipation
Interventions
Constipation treatment
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

NCT00943995
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Dialysis
Interventions
somatropin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT01251575
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome, Adult Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Diffuse Large B-Cell Lymphoma, Childhood Myelodysplastic Syndrome, Childhood Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Mantle Cell Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain

NCT01159119
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUR-1066-A, Zenpep, EUR-1066-B
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

NCT01218477
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

NCT05032157
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open-label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 16, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Physical and Emotional Health of Caregivers for People Who Have Had Stem Cell Transplants

NCT01468857
View directory record Official record
Conditions
Stress, Family Caregivers
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

NCT00186641
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
high dose chemo and auto hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

NCT06021054
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tailoring Mindfulness Interventions for Families Managing Chronic Health Conditions

NCT05271851
View directory record Official record
Conditions
Mindfulness, Chronic Disease
Interventions
Not listed
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 16, 2026, 10:45 AM EDT
Withdrawn Not applicable Interventional

Transverse Tibial Transport for Chronic Limb-Threatening Ischemia (CLTI)

NCT07175129
View directory record Official record
Conditions
Chronic Limb Threatening Ischemia
Interventions
Transverse Tibial Bone Transport, TrueLok Elevate
Procedure · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 16, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 10:45 AM EDT